DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025" report to their offering.
The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.
The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.
Key Topics Covered:
1 Research Methodology & Scope
2 Executive Summary
3 Market VariabAllyamines, Trends& Scope
4 Market Categorization 1: Drug Class Estimates & Trend Analysis
5 Market Categorization : Indication Estimates & Trend Analysis
6 Market Categorization : Regional Estimates & Trend Analysis, by Drug Class and Indications
7 Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/4dfxv7/antifungal_drugs